

-Remarks-

Applicants gratefully acknowledge the allowance of claims 1 - 3 and respectfully request that the Examiner consider the amendments made herein to those claims to correct typographical and grammatical errors and to add language directed to pharmaceutically acceptable salts.

Entry of the above amendments and reconsideration and withdrawal of the objection to claims 4 - 9 and 12 - 13 is respectfully requested. Claim 1 was amended to correct typographical and grammatical errors found in the original claim. Claims 2 - 9 were amended to add "or a pharmaceutically acceptable salt" to each of those claims. Support for this amendment may be found in the specification at page 20, line 32 to page 22, line 5. Claims 4 - 9, 12 and 13 were amended to remove multiple dependency therefrom and to make each claim dependent solely from claim 1. Claim 9 was amended to name explicitly the compounds of Examples 1 to 26 rather than refer to the Examples. Claim 12 was amended so that the method claim is correctly phrased as a method of treating and to define the diseases, disorders and conditions which are treatable by the method. Support for this amendment may be found in the specification at page 41, line 9 to page 42, line 20. Claim 13 was amended to add the phrase "pharmaceutical composition comprising a." Applicants have canceled claims 10 and 11, without waiver or prejudice, as being written in non-statutory formats. Applicants have added new claim 14 directed to a method of treating asthma and COPD. Support for this amendment is in the specification at page 41, line 9 to page 42, line 20.

Applicants submit that no new subject matter has been added by any of these amendments. Applicants reserve the right to file continuation applications directed to any canceled or other unclaimed subject matter of this application.

The objections to the claims.

The Examiner has objected to claims 4 - 8 and 10 - 13 under 37 C.F.R. §1.75(c) as being in improper form because a multiple dependent claim cannot depend from another multiple dependent claim. Applicants submit that original claim 4, a multiple dependent claim, did not depend from another multiple dependent claim and therefore did not violate 37 C.F.R. §1.75(c). However, Applicants have amended the claims as described above to remove all multiple dependent claim language from claims 4 - 8, 12 and 13.

The Examiner has also objected to claim 9 because that claim refers to "examples 1 to 26." Applicants have amended claim 9 hereinabove to correct this deficiency by adding the names of each of the compounds of Examples 1 to 26 explicitly into the claim.

Applicants respectfully request that the Examiner reconsider and withdraw the objections to claims 4 - 9, 12 and 13 in light of the above amendments.


-Conclusion-

Applicants, having responded to all points and concerns raised by the Examiner, believe this application to be in condition for allowance. An early and favorable action is respectfully requested.

Respectfully submitted,

Dated: March 28, 2007

Pfizer Inc.
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 441-5910



Robert T. Rorlau
Attorney for Applicants
Reg. No. 36,257